vs
Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $487.7M, roughly 1.6× CLOVER HEALTH INVESTMENTS, CORP.). Insulet Corporation runs the higher net margin — 13.0% vs -10.1%, a 23.1% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 31.2%). Insulet Corporation produced more free cash flow last quarter ($48.2M vs $-69.0M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 18.6%).
Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
CLOV vs PODD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $487.7M | $783.7M |
| Net Profit | $-49.3M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | -10.1% | 18.7% |
| Net Margin | -10.1% | 13.0% |
| Revenue YoY | 44.7% | 31.2% |
| Net Profit YoY | -123.2% | 0.9% |
| EPS (diluted) | — | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $487.7M | $783.7M | ||
| Q3 25 | $496.6M | $706.3M | ||
| Q2 25 | $477.6M | $649.1M | ||
| Q1 25 | $462.3M | $569.0M | ||
| Q4 24 | $337.0M | $597.5M | ||
| Q3 24 | $331.0M | $543.9M | ||
| Q2 24 | $356.3M | $488.5M | ||
| Q1 24 | $346.9M | $441.7M |
| Q4 25 | $-49.3M | $101.6M | ||
| Q3 25 | $-24.4M | $87.6M | ||
| Q2 25 | $-10.6M | $22.5M | ||
| Q1 25 | $-1.3M | $35.4M | ||
| Q4 24 | $-22.1M | $100.7M | ||
| Q3 24 | $-9.2M | $77.5M | ||
| Q2 24 | $7.4M | $188.6M | ||
| Q1 24 | $-19.2M | $51.5M |
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | 24.5% | 69.3% | ||
| Q2 24 | 30.3% | 67.7% | ||
| Q1 24 | 23.6% | 69.5% |
| Q4 25 | -10.1% | 18.7% | ||
| Q3 25 | -4.9% | 16.7% | ||
| Q2 25 | -2.2% | 18.7% | ||
| Q1 25 | -0.3% | 15.6% | ||
| Q4 24 | -6.4% | 18.3% | ||
| Q3 24 | -2.7% | 16.2% | ||
| Q2 24 | 2.0% | 11.2% | ||
| Q1 24 | -6.5% | 12.9% |
| Q4 25 | -10.1% | 13.0% | ||
| Q3 25 | -4.9% | 12.4% | ||
| Q2 25 | -2.2% | 3.5% | ||
| Q1 25 | -0.3% | 6.2% | ||
| Q4 24 | -6.6% | 16.9% | ||
| Q3 24 | -2.8% | 14.2% | ||
| Q2 24 | 2.1% | 38.6% | ||
| Q1 24 | -5.5% | 11.7% |
| Q4 25 | — | $1.42 | ||
| Q3 25 | — | $1.24 | ||
| Q2 25 | — | $0.32 | ||
| Q1 25 | — | $0.50 | ||
| Q4 24 | — | $1.38 | ||
| Q3 24 | — | $1.08 | ||
| Q2 24 | — | $2.59 | ||
| Q1 24 | — | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.3M | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $308.7M | $1.5B |
| Total Assets | $541.0M | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $78.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $194.5M | — | ||
| Q3 24 | $288.0M | — | ||
| Q2 24 | $254.8M | — | ||
| Q1 24 | $208.3M | — |
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | $308.7M | $1.5B | ||
| Q3 25 | $340.9M | $1.4B | ||
| Q2 25 | $344.2M | $1.5B | ||
| Q1 25 | $336.1M | $1.3B | ||
| Q4 24 | $341.1M | $1.2B | ||
| Q3 24 | $342.2M | $1.1B | ||
| Q2 24 | $324.9M | $998.4M | ||
| Q1 24 | $292.5M | $790.7M |
| Q4 25 | $541.0M | $3.2B | ||
| Q3 25 | $559.7M | $3.0B | ||
| Q2 25 | $575.0M | $3.5B | ||
| Q1 25 | $583.7M | $3.5B | ||
| Q4 24 | $580.7M | $3.1B | ||
| Q3 24 | $653.0M | $3.0B | ||
| Q2 24 | $674.2M | $2.9B | ||
| Q1 24 | $671.8M | $2.6B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-66.9M | $183.3M |
| Free Cash FlowOCF − Capex | $-69.0M | $48.2M |
| FCF MarginFCF / Revenue | -14.1% | 6.2% |
| Capex IntensityCapex / Revenue | 0.4% | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $-69.2M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-66.9M | $183.3M | ||
| Q3 25 | $12.1M | $125.7M | ||
| Q2 25 | $5.4M | $196.5M | ||
| Q1 25 | $-16.3M | $63.8M | ||
| Q4 24 | $34.8M | $147.7M | ||
| Q3 24 | $50.0M | $98.5M | ||
| Q2 24 | $44.8M | $96.5M | ||
| Q1 24 | $25.9M | $87.6M |
| Q4 25 | $-69.0M | $48.2M | ||
| Q3 25 | $11.4M | $100.1M | ||
| Q2 25 | $4.8M | $177.9M | ||
| Q1 25 | $-16.5M | $51.5M | ||
| Q4 24 | $33.3M | $94.1M | ||
| Q3 24 | $49.6M | $71.8M | ||
| Q2 24 | $44.4M | $74.0M | ||
| Q1 24 | $25.5M | $65.5M |
| Q4 25 | -14.1% | 6.2% | ||
| Q3 25 | 2.3% | 14.2% | ||
| Q2 25 | 1.0% | 27.4% | ||
| Q1 25 | -3.6% | 9.1% | ||
| Q4 24 | 9.9% | 15.7% | ||
| Q3 24 | 15.0% | 13.2% | ||
| Q2 24 | 12.5% | 15.1% | ||
| Q1 24 | 7.3% | 14.8% |
| Q4 25 | 0.4% | 17.2% | ||
| Q3 25 | 0.1% | 3.6% | ||
| Q2 25 | 0.1% | 2.9% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.5% | 9.0% | ||
| Q3 24 | 0.1% | 4.9% | ||
| Q2 24 | 0.1% | 4.6% | ||
| Q1 24 | 0.1% | 5.0% |
| Q4 25 | — | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 6.04× | 0.51× | ||
| Q1 24 | — | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLOV
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
